SOURCE: GeoVax, Inc.

GeoVax, Inc.

June 25, 2015 17:44 ET

AFRICAN LEADERSHIP MAGAZINE to Present Two Prestigious Awards to GeoVax and Dr. Robert McNally

GeoVax's Efforts to Develop HIV/AIDS and Ebola Vaccines Recognized

ATLANTA, GA--(Marketwired - Jun 25, 2015) - GeoVax Labs, Inc. (OTCQB: GOVX) announced today that Robert McNally Ph.D., President & CEO, will receive the African Health Impact Award from The African Leadership Magazine during a ceremony to be held Friday, June 26th at 6:30 pm. He will also be inducted into the African Leadership Hall of Fame. The award recognizes GeoVax's significant ongoing role in the fight against HIV/AIDS and Ebola in Africa and its commitment to helping curb epidemics in the African continent.

Dr. McNally stated, "I am thrilled and proud to receive this honor on behalf of the dedicated team at GeoVax because it brings attention to the innovative work we are doing at GeoVax. Every day, too many people are still dying of AIDS and we believe our vaccine is the best hope for finally making that tragic reality a part of our past."

The African Leadership Magazine (http://africanleadership.co.uk) has a proud history of innovation, entrepreneurship and development. This evening of recognition also will highlight accomplishments from Mike Onolememen and Mrs. Naomi King.

About GeoVax

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines against infectious diseases using our novel vaccine platform. Our current development programs are focused on vaccines against Ebola and Marburg viruses, and Human Immunodeficiency Virus (HIV). We believe our technology and vaccine development expertise is well-suited for a wide variety of human infectious diseases for which there is an unmet medical need, and we intend to pursue expansion of our product pipeline.

Our vaccine platform supports production of non-infectious virus-like particles (VLPs) from the cells of the person receiving the vaccine. Producing non-infectious virus-like particles in the person being vaccinated circumvents the need to purify virus-like particles for inoculation. The production of virus-like particles in the person being vaccinated mimics a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent and control the target infection should it appear.

Clinical trials for GeoVax's preventive HIV vaccines have been conducted by the US National Institutes of Health-supported HIV Vaccine Trials Network (HVTN) with funding from the National Institute of Allergy and Infectious Disease (NIAID). Overall, GeoVax's vaccines, in various doses and combinations, have been tested in 500 humans. For more information, go to www.geovax.com.

Contact Information